Abstract
To the Editor: I admire the careful work presented in the recent article by Salmon and his co-workers,1 and I agree with the opinion expressed in the accompanying editorial2 that this article may have a profound effect on the treatment of cancer. The general statement of the authors, however, that the bioassay presented can identify drugs to which a patient's tumor is resistant, and thus can eliminate the need for empirical trials, is premature and dangerous. It may be correct for alkylating agents, and for adriamycin and bleomycin. Their data pertain to these drugs. The authors include methotrexate in their. No extract is available for articles shorter than 400 words.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 721 |
| Number of pages | 1 |
| Journal | New England Journal of Medicine |
| Volume | 299 |
| Issue number | 13 |
| DOIs | |
| State | Published - Sep 28 1978 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
In Vitro Sensitivity of Cancer Cells to Antitumor Agents. / Gratwohl, Alois A.; Salmon, Sydney E.; Hamburger, Anne W.; Soehnlen, Barbara; Durie, Brian G.M.; Alberts, David S; Moon, Thomas E.
In: New England Journal of Medicine, Vol. 299, No. 13, 28.09.1978, p. 721.Research output: Contribution to journal › Letter
}
TY - JOUR
T1 - In Vitro Sensitivity of Cancer Cells to Antitumor Agents
AU - Gratwohl, Alois A.
AU - Salmon, Sydney E.
AU - Hamburger, Anne W.
AU - Soehnlen, Barbara
AU - Durie, Brian G.M.
AU - Alberts, David S
AU - Moon, Thomas E.
PY - 1978/9/28
Y1 - 1978/9/28
N2 - To the Editor: I admire the careful work presented in the recent article by Salmon and his co-workers,1 and I agree with the opinion expressed in the accompanying editorial2 that this article may have a profound effect on the treatment of cancer. The general statement of the authors, however, that the bioassay presented can identify drugs to which a patient's tumor is resistant, and thus can eliminate the need for empirical trials, is premature and dangerous. It may be correct for alkylating agents, and for adriamycin and bleomycin. Their data pertain to these drugs. The authors include methotrexate in their. No extract is available for articles shorter than 400 words.
AB - To the Editor: I admire the careful work presented in the recent article by Salmon and his co-workers,1 and I agree with the opinion expressed in the accompanying editorial2 that this article may have a profound effect on the treatment of cancer. The general statement of the authors, however, that the bioassay presented can identify drugs to which a patient's tumor is resistant, and thus can eliminate the need for empirical trials, is premature and dangerous. It may be correct for alkylating agents, and for adriamycin and bleomycin. Their data pertain to these drugs. The authors include methotrexate in their. No extract is available for articles shorter than 400 words.
UR - http://www.scopus.com/inward/record.url?scp=0018078776&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018078776&partnerID=8YFLogxK
U2 - 10.1056/NEJM197809282991313
DO - 10.1056/NEJM197809282991313
M3 - Letter
VL - 299
SP - 721
JO - New England Journal of Medicine
JF - New England Journal of Medicine
SN - 0028-4793
IS - 13
ER -